Medicare Enrolled

Dr. Anibal Drelichman, MD

Medical Oncology · Southfield, MI
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
22301 FOSTER WINTER DR, Southfield, MI 48075
2485520620
Registered in NPPES since 2006
NPI: 1740222447 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Drelichman from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Drelichman? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Drelichman

Dr. Anibal Drelichman is a medical oncology specialist in Southfield, MI, with 20 years of NPI registration. Based on federal Medicare data, Dr. Drelichman performed 11,791 Medicare services in 2023. These records do not provide a deduplicated patient total.

Between the years covered by Open Payments, Dr. Drelichman received a total of $14,372 from 60 pharmaceutical and/or device companies across 294 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Drelichman is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 20 years of NPI registration ▲ Top 25% volume in MI $14,372 industry payments

Medicare Practice Summary — 2023

Medicare Utilization ↗
11,791
Medicare services
Top 25% in MI for medical oncology
Not available
Unique patients (not deduplicated)
$19
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Denosumab injection (Prolia/Xgeva) 10,980 $18 $34
Drug injection, under skin or into muscle
A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle.
251 $10 $42
Blood draw (venipuncture)
Insertion of a needle into a vein to collect a blood sample.
161 $8 $10
Complete blood count (CBC) with differential
An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells.
153 $8 $18
Zoledronic acid injection, 1 mg
An injection of zoledronic acid administered at a dose of 1 mg.
86 $7 $118
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
80 $94 $152
Intravenous infusion, 1 hour or less
Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less.
56 $47 $172
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
24 $69 $100
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
0.5% high complexity
96.0% medium
3.5% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$14,372
Total received (2018-2024)
Avg $2,053/year across 7 years
Top 19% in MI for medical oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
60
Companies
294
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →

Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$940
2023
$1,408
2022
$291
2021
$30
2020
$100
2019
$10,191
2018
$1,413

Payments by company (2024)

SOBI, INC
$176
Aveo Pharmaceuticals, Inc.
$107
Janssen Biotech, Inc.
$84
Merck Sharp & Dohme LLC
$71
Eisai Inc.
$62
GENZYME CORPORATION
$47
RECORDATI_RARE_DISEASES_INC.
$46
GlaxoSmithKline, LLC.
$42
Genentech USA, Inc.
$40
Daiichi Sankyo Inc.
$37
Celgene Corporation
$34
BeiGene USA, Inc.
$30
Exelixis Inc.
$24
Pharmacosmos Therapeutics Inc.
$23
Apellis Pharmaceuticals, Inc.
$22
Lilly USA, LLC
$21
Incyte Corporation
$21
AstraZeneca Pharmaceuticals LP
$20
TAIHO ONCOLOGY, INC.
$19
Astellas Pharma US Inc
$15
Top 3 companies account for 39.0% of 2024 payments
All-time payments by company (2018-2024) ›
Novartis Pharmaceuticals Corporation
$8,583
Janssen Biotech, Inc.
$450
Gilead Sciences, Inc.
$396
AstraZeneca Pharmaceuticals LP
$345
Astellas Pharma US Inc
$319
Merck Sharp & Dohme Corporation
$276
Pharmacyclics LLC, An AbbVie Company
$258
Genentech USA, Inc.
$233
Eisai Inc.
$217
Daiichi Sankyo Inc.
$210
Smith+Nephew, Inc.
$207
PFIZER INC.
$188
SOBI, INC
$176
Amgen Inc.
$173
Ipsen Biopharmaceuticals, Inc
$138
Merck Sharp & Dohme LLC
$136
Clovis Oncology, Inc.
$125
E.R. Squibb & Sons, L.L.C.
$123
ViiV Healthcare Company
$121
Lilly USA, LLC
$113
Aveo Pharmaceuticals, Inc.
$107
EMD Serono, Inc.
$103
SANOFI-AVENTIS U.S. LLC
$100
AVEO Pharmaceuticals, Inc.
$98
GENZYME CORPORATION
$82
Celgene Corporation
$81
Allergan Inc.
$67
Taiho Oncology, Inc.
$66
Seagen Inc.
$65
BeiGene USA, Inc.
$63
Alexion Pharmaceuticals, Inc.
$56
Jazz Pharmaceuticals Inc.
$54
RECORDATI_RARE_DISEASES_INC.
$46
GlaxoSmithKline, LLC.
$42
EISAI INC.
$41
Pharmacosmos Therapeutics Inc.
$39
AbbVie, Inc.
$37
Exelixis Inc.
$36
AbbVie Inc.
$30
MEDIVATION FIELD SOLUTIONS LLC
$26
Bayer Healthcare Pharmaceuticals Inc.
$24
Myriad Genetic Laboratories, Inc.
$24
Apellis Pharmaceuticals, Inc.
$22
Incyte Corporation
$21
Takeda Pharmaceuticals U.S.A., Inc.
$21
TerSera Therapeutics LLC
$20
Kite Pharma, Inc.
$19
TAIHO ONCOLOGY, INC.
$19
ARRAY BIOPHARMA INC
$18
TESARO, Inc.
$18
AMAG Pharmaceuticals, Inc.
$17
SERVIER PHARMACEUTICALS LLC
$17
Mirati Therapeutics, Inc.
$17
G1 Therapeutics, Inc.
$17
Boehringer Ingelheim Pharmaceuticals, Inc.
$16
Teva Pharmaceuticals USA, Inc.
$15
Partner Therapeutics, Inc.
$14
Verastem, Inc.
$13
Bayer HealthCare Pharmaceuticals Inc.
$12
Janssen Pharmaceuticals, Inc
$6
Top 3 companies account for 65.6% of all-time payments
Associated products mentioned in payments ›
ADAKVEO · ALIMTA · AVYCAZ · Abraxane · Acticoat Range · Alecensa · Aliqopa · Allevyn Life · Aranesp · BENDEKA · BOSULIF · BRAFTOVI · BRUKINSA · Bavencio · Blincyto · CABLIVI · CABOMETYX · CALQUENCE · CARVYKTI · COSELA · CRESEMBA · CYRAMZA · Cabometyx · Columvi · Copiktra · Creon · DALVANCE · DARZALEX · DOPTELET · DOVATO · Descovy · ENHERTU · ENJAYMO · Empaveli · Enhertu · Epclusa · FERAHEME · FOTIVDA · GARDASIL · GARDASIL9 · GILOTRIF · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · Imbruvica · JADENU · JAKAFI · JEVTANA · JULUCA · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LONSURF · LYNPARZA · Lenvima · Leukine · Lonsurf · Lunsumio · MEKINIST · MONOFERRIC · MYLOTARG · MYRISK · Neulasta · Nplate · OJJAARA · OPDIVO · PADCEV · PICO 7 Single Use Negative Pressure Wound Therapy · PREZCOBIX · PROMACTA · Padcev · Perjeta · Pomalyst · REBLOZYL · Revlimid · Rubraca · SARCLISA · SOLIRIS · SOMATULINE DEPOT · SPRYCEL · SUTENT · SYLVANT · Stivarga · Symtuza · TAFINLAR · TAGRISSO · TASIGNA · TECENTRIQ · TECVAYLI · TEFLARO · TEPMETKO · TRIUMEQ · TUKYSA · TUMOR LYSIS SYNDROME - DISEASE · Tibsovo · Trodelvy · ULTOMIRIS · VENCLEXTA · VERZENIO · VONJO · VOTRIENT · VYXEOS · Venclexta · XALKORI · XARELTO · XTANDI · Xtandi · ZEJULA · ZEPZELCA · ZYTIGA · Zoladex
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Looking for a medical oncology specialist in Southfield?
Compare medical oncologists in the Southfield area by procedure volume, costs, and industry payment transparency.
Browse medical oncologists nearby

Geographic Context

Medical oncologists in nearby ZIP areas
36
County median income
$95,296
Nearest hospital to ZIP centroid (approximate)
ASCENSION PROVIDENCE HOSPITAL, SOUTHFIELD AND NOVI
0.0 mi

Data Sources

Provider Registry NPPES NPPES snapshot; verify current record
Medicare Enrollment PECOS PECOS snapshot
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not included N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Drelichman is a mixed practice specialist, with above-average Medicare volume (top 25% in MI), with 20 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Drelichman experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Dr. Drelichman performed 10,980 denosumab injection (prolia/xgeva) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Drelichman receive payments from pharmaceutical companies?
Yes. Dr. Drelichman received a total of $14,372 from 60 companies across 294 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Drelichman's costs compare to other medical oncologists in Southfield?
Dr. Drelichman's average Medicare payment per service is $19. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Drelichman) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
About this page

This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Industry payment disclosure alone establishes neither wrongdoing nor legality. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →